<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187743</url>
  </required_header>
  <id_info>
    <org_study_id>P160935J</org_study_id>
    <secondary_id>2017-002050-36</secondary_id>
    <nct_id>NCT03187743</nct_id>
  </id_info>
  <brief_title>Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone</brief_title>
  <acronym>DECOR</acronym>
  <official_title>Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is a multicentre prospective pharmacokinetic study. The clinical and&#xD;
      biological data will be collected in the framework of a prospective study. The drug to be&#xD;
      evaluated is a glucocorticoid routinely used to treat Systemic lupus erythematosus (SLE)&#xD;
      patient. Initial dose of prednisone must be oral and at least 0.5mg/Kg/day, but the precise&#xD;
      dosage and the tapering regimen will be determined according to the clinical judgment of the&#xD;
      investigator. The duration of the research period for each patient will be 3 months. Three&#xD;
      visits (which are all usual care visits) will be needed within the 3 months of the study for&#xD;
      collecting data and/or blood sampling&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Until now, glucocorticoids always play a leading role in the lupus treatment, and the lupus's&#xD;
      prognosis has been greatly improved by the treatment of serious flare-ups with a combination&#xD;
      of high-dose corticosteroids and immunosuppressants, notably mycophenolate mofetil (MMF)&#xD;
      together with hydroxychloroquine (Plaquenil), survival at 10 years being 70 to 90%. However,&#xD;
      corticosteroid treatment is also a major cause of morbidity and mortality, and with 60 years&#xD;
      of experience, consensus about &quot;appropriate&quot; dosages, route of administration and tapering&#xD;
      regimes has not been reached. In addition, there is a large variability in clinical response&#xD;
      to corticosteroid therapy which may be attributed to heterogeneity of SLE, drugs interaction&#xD;
      or to environmental and genetic factors, especially to polymorphism of the MDR (multi-drug&#xD;
      resistance) -1 and NR3C1 (glucocorticoid nuclear receptor subfamily 3, group C, member 1).&#xD;
      There are no previous studies investigating the role of MDR-1 and NR3C1 genes polymorphisms&#xD;
      in the response to corticosteroids in lupus patients Drug monitoring of immunosuppressive&#xD;
      drugs has been largely explored in renal transplantation and in a lesser extend in SLE&#xD;
      (especially for mycophenolic acid). Relationship between prednisolone PK and clinical&#xD;
      efficacy/toxicity have been also shown previously especially in renal transplant population.&#xD;
      In patients with SLE, only two small series (8 children, 25 adults) have explored this&#xD;
      relationship, and suggested that SLE activity and corticosteroid toxicity might be related to&#xD;
      prednisolone AUC. Thus, limited data suggest that prednisone monitoring may optimize&#xD;
      treatment efficacy and minimize adverse events.&#xD;
&#xD;
      The DECOR study will aim :&#xD;
&#xD;
        1. to search for relationship between prednisolone PK and SLE disease activity in a large&#xD;
           series of patients in order to improve the rational of prednisone doses in lupus&#xD;
           patients&#xD;
&#xD;
        2. to identify pharmacogenetic factors influencing the response to steroid in order to&#xD;
           identify patients sharing a high probability of being responders or resistant to&#xD;
           corticosteroids.&#xD;
&#xD;
      This approach could be applied to all inflammatory diseases requiring prolonged&#xD;
      corticosteroid treatment, and thus, be a major progress in the use of this old treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SELENA-SLEDAI score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary parameters : volume of distribution</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary parameters : elimination clearance</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary parameters : absorption constant</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary parameters : trough concentration</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary parameters : maximum concentration</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary parameters : Area Under Curve (AUC)</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary parameters : elimination half-life</measure>
    <time_frame>Day 0, 1 month, 3 months</time_frame>
    <description>To study the pharmacokinetics of prednisolone in a population of patients with SLE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetics/dynamics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples at 3 visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples at 3 visits :&#xD;
V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis&#xD;
V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis&#xD;
V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank</description>
    <arm_group_label>Pharmacokinetics/dynamics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged ≥ 6 years&#xD;
&#xD;
          -  Patient who met the American College of Rheumatology criteria (ACR) or the Systemic&#xD;
             Lupus International Collaborating Clinics Classification (SLICC) for systemic lupus&#xD;
             erythematosus.&#xD;
&#xD;
          -  Patients needs (re)initiation of oral prednisone regimen at least at 0.5 mg/Kg/d(or&#xD;
             &gt;30mg/d for patients &gt;60 kg) in combination with mycophenolate mofetyl or mycofenolic&#xD;
             acid or cyclophosphamide at usual dose including :&#xD;
&#xD;
             i) patient who receives bolus of methylprednisolone the week before and/or the week&#xD;
             after inclusion for treating the lupus flare ii) patient who was previously treated by&#xD;
             a low-prednisone dose (≤ 7.5 mg/d in patients ≥ 60 kg and ≤ 0.1 mg/kd/d in patient &lt;&#xD;
             60 kg).&#xD;
&#xD;
        iii) patient who was previously treated by prednisone ≥ 0,5 mg/kg/d (or &gt;30mg/d for&#xD;
        patients &gt;60 kg) but stopped since at least one month before inclusion&#xD;
&#xD;
          -  Patient with stable doses of other immunosuppressive or biological drugs before&#xD;
             inclusion (at least 15 days for Imurel, Methotrexate, Tacrolimus ; at least 6 months&#xD;
             for Rituximab, Belimumab) and during the 3 months of patient participation in the&#xD;
             study.&#xD;
&#xD;
          -  Signed informed consent form by the patient (if aged ≥ 18 years), or by the parents /&#xD;
             legal guardian and patient's agreement (if aged &lt; 18 years)&#xD;
&#xD;
          -  Patient affiliated to the health insurance system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presents contraindications to corticosteroids&#xD;
&#xD;
          -  Patient presents contraindications to MMF, mycofenolic acid or cyclophosphamide for&#xD;
             patient receiving immunosupressor&#xD;
&#xD;
          -  Patient cannot be treated by oral way&#xD;
&#xD;
          -  Patient whose physician has planned to stop prednisone in less than 3 months&#xD;
&#xD;
          -  Patient (or parents for minor) are unable to give a written informed consent for&#xD;
             physical or psychical reasons&#xD;
&#xD;
          -  Patient disagrees with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela SEMERARO</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte BADER-MEUNIER, MD, PhD</last_name>
    <phone>+33 (0) 1 44 49 43 32</phone>
    <email>brigitte.bader-meunier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure CHOUPEAUX, Master</last_name>
    <phone>+33 1 44 38 17 11</phone>
    <email>laure.choupeaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte BADER-MEUNIER, MD, PhD</last_name>
      <phone>+33 (0) 1 44 49 43 32</phone>
      <email>brigitte.bader-meunier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. Review.</citation>
    <PMID>15634032</PMID>
  </reference>
  <reference>
    <citation>Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA. Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther. 2011 Oct;33(10):1524-36. doi: 10.1016/j.clinthera.2011.09.015. Epub 2011 Oct 7.</citation>
    <PMID>21982386</PMID>
  </reference>
  <reference>
    <citation>Piotrowski P, Burzynski M, Lianeri M, Mostowska M, Wudarski M, Chwalinska-Sadowska H, Jagodzinski PP. Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus. Folia Histochem Cytobiol. 2007;45(4):339-42.</citation>
    <PMID>18165172</PMID>
  </reference>
  <reference>
    <citation>Du J, Li M, Zhang D, Zhu X, Zhang W, Gu W, Feng Y, Zhai X, Ling C. Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R108. doi: 10.1186/ar2763. Epub 2009 Jul 14.</citation>
    <PMID>19594946</PMID>
  </reference>
  <reference>
    <citation>Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007 Sep 15;275(1-2):71-8. Epub 2007 Jun 2. Review.</citation>
    <PMID>17630118</PMID>
  </reference>
  <reference>
    <citation>Derijk RH, de Kloet ER. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol. 2008 Apr 7;583(2-3):303-11. doi: 10.1016/j.ejphar.2007.11.072. Epub 2008 Jan 30. Review.</citation>
    <PMID>18321483</PMID>
  </reference>
  <reference>
    <citation>Mwinyi J, Wenger C, Eloranta JJ, Kullak-Ublick GA. Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients. World J Gastroenterol. 2010 Aug 21;16(31):3888-96.</citation>
    <PMID>20712049</PMID>
  </reference>
  <reference>
    <citation>Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010 Jan;75(1):1-12. doi: 10.1016/j.steroids.2009.09.002. Epub 2009 Oct 7. Review.</citation>
    <PMID>19818358</PMID>
  </reference>
  <reference>
    <citation>van Rossum EFC, van den Akker ELT. Glucocorticoid resistance. Endocr Dev. 2011;20:127-136. doi: 10.1159/000321234. Epub 2010 Dec 16. Review.</citation>
    <PMID>21164266</PMID>
  </reference>
  <reference>
    <citation>Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19.</citation>
    <PMID>23873876</PMID>
  </reference>
  <reference>
    <citation>Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev. 2013 Mar;12(5):617-28. doi: 10.1016/j.autrev.2012.12.001. Epub 2012 Dec 8. Review.</citation>
    <PMID>23232124</PMID>
  </reference>
  <reference>
    <citation>Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013 Sep;15(9):360. doi: 10.1007/s11926-013-0360-0. Review.</citation>
    <PMID>23888367</PMID>
  </reference>
  <reference>
    <citation>Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801-8.</citation>
    <PMID>10943870</PMID>
  </reference>
  <reference>
    <citation>Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, Petri M. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015 Mar 11;2(1):e000066. doi: 10.1136/lupus-2014-000066. eCollection 2015.</citation>
    <PMID>25861455</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus erythematosus</keyword>
  <keyword>Systemic</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

